People

Britt Meelby Jensen

Britt Meelby Jensen

Member of the Novo Holdings Board since 2022. Vice Chair of the Board since 2025. Britt Meelby Jensen was born in 1973 and is a Danish national. She received a MSc in International Marketing and Management from Copenhagen Business School in Denmark and furthermore received an MBA from Solvay Business School (Université Libre de Bruxelles) in Brussels. Between 2000-2002, Britt Meelby Jensen worked as a Management Consultant in McKinsey & Company before she joined Novo Nordisk A/S in 2002, where she held several global commercial leadership roles. Hereafter she has held CEO roles at Dako A/S, Zealand Pharma A/S, and at the Swedish MedTech company, Atos Medical AB. In 2022, Britt Meelby Jensen was appointed as CEO of Ambu A/S where she had served as Board member since 2019. Other Board Positions and Management Duties: CEO, Ambu A/S, Denmark Board Member, Novo Nordisk A/S, Denmark Board member of the Industry Association for Employers in Denmark, IAD, and the Confederation of Danish Industry, DI

Roles

Novo Holdings

External Advisory Group member (published outside affiliation: Vice Chair — Board of Directors, Advisory Group)

Current